Fidson Healthcare Plc records 30.28% increase in 2020 9M revenues

Fidson Healthcare Plc – a leading pharmaceutical manufacturing company, reported revenues of N13.65 billion in 2020 9M, compared to N10.48 billion same period in 2019.

Key highlights for 2020 9M

  • Revenues increased to N13.65 billion, +30.28% YoY.
  • Revenues from ethical drugs increased to N8.08 billion, +44.64% YoY.
  • Revenues from over the counter increased to N5.57 billion +13.95% YoY.
  • Other operating income increased to N210.07 million, +10.30% YoY.
  • Administrative expenses increased to N2.72 billion, +25.93% YoY.
  • Selling and distribution expenses increased to 1.86 billion, +75.13% YoY.
  • Finance cost decreased to N951.38 million, -31.56% YoY.
  • Pre-tax profits increased to N1.44 billion, +257.74% YoY.

Bottom Line

Fidson Healthcare Plc recorded a major increase in its ethical drugs and over the counter revenue-generating units. The rise in revenues is understandable, considering the recent rise in revenues of pharmaceutical companies due to the COVID-19 pandemic. The company also increased significantly in the period, despite its rising expenses. This was partly aided by declined finance cost and increased other operating income.


This site uses Akismet to reduce spam. Learn how your comment data is processed.

Inline Feedbacks
View all comments